The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1

Eur J Pharmacol. 1993 Dec 21;250(3):473-6. doi: 10.1016/0014-2999(93)90037-i.

Abstract

Riluzole is believed to exert its anticonvulsant and neuroprotective actions by reducing glutamate release. This study demonstrated that 10-30 microM riluzole reduces the K(+)-evoked release of glutamate and aspartate from slices of hippocampal area CA1. Only higher concentrations reduced gamma-aminobutyrate (GABA) release. These actions of riluzole were not occluded by tetrodotoxin. Riluzole did not diminish the ability of glutamate analogues to depolarize CA1 pyramidal cells, as determined from grease-gap recordings. Therefore the anticonvulsant and neuroprotective actions of riluzole in the hippocampus may be at least partly explained by its ability to inhibit glutamate/aspartate release from synaptic terminals.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Aspartic Acid / metabolism*
  • Excitatory Amino Acid Antagonists
  • Female
  • Glutamates / metabolism*
  • Hippocampus / drug effects*
  • Hippocampus / metabolism
  • Potassium / pharmacology
  • Pyramidal Cells / drug effects
  • Pyramidal Cells / physiology
  • Rats
  • Rats, Sprague-Dawley
  • Riluzole
  • Thiazoles / pharmacology*
  • gamma-Aminobutyric Acid / metabolism

Substances

  • Excitatory Amino Acid Antagonists
  • Glutamates
  • Thiazoles
  • Aspartic Acid
  • gamma-Aminobutyric Acid
  • Riluzole
  • Potassium